Please visit answersincme.com/860/240201307-replay2 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Aly-Khan A. Lalani, MD, FRCPC; Normand Blais, MD, MSc; Krista Noonan, BSc, MD, FRCPC and Eleftherios Soleas, PhD In this activity, experts in managing urothelial carcinoma and renal cell carcinoma (RCC) from across Canada discuss evidence-based strategies for integrating the latest systemic therapies into practice to optimize outcomes for patients with advanced urothelial carcinoma and resected/advanced RCC, with insights into regional practice considerations. Upon completion of this activity, participants should be better able to: Incorporate the latest evidence on frontline combination regimens into treatment planning for advanced urothelial carcinoma; Identify strategies to optimally incorporate adjuvant immunotherapy into treatment plans for eligible patients with early-stage renal cell carcinoma (RCC); and Evaluate how current evidence and guidelines may inform optimal sequencing of therapies in later-line settings for patients with advanced RCC.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related